<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596477</url>
  </required_header>
  <id_info>
    <org_study_id>MST-188-09</org_study_id>
    <nct_id>NCT02596477</nct_id>
  </id_info>
  <brief_title>Evaluation of Vepoloxamer in Chronic Heart Failure</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vepoloxamer Injection, 22.5% (Sodium-Free) in Ambulatory Subjects With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mast Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mast Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether vepoloxamer can provide a blood chemical
      marker and functional benefit to damaged heart muscle cells. This will be evaluated by
      measurement of blood-based laboratory markers, exercise tolerance, and echocardiograms. In
      addition, the safety and blood levels of vepoloxamer in subjects with chronic heart failure
      will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated for administrative reasons not related to safety or efficacy
  </why_stopped>
  <start_date>October 2015</start_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with a change in cardiac biomarkers ultra-high sensitive troponin I and NT-proBNP</measure>
    <time_frame>Study Day 1 through Study Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with a change in Six Minute Walk test</measure>
    <time_frame>Study Day 1 to Study Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with a change in Borg dyspnea index</measure>
    <time_frame>Study Day 1 to Study Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with a change in Minnesota Living with Heart Failure Questionnaire®</measure>
    <time_frame>Study Day 1 to Study Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with a change in left ventricular end diastolic volume index</measure>
    <time_frame>Study Day 1 to Study Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with treatment-related adverse events as assessed by CTCAE v 4.03</measure>
    <time_frame>Study Day 1 to Study Day 30</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Vepoloxamer - Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vepoloxamer injection administered intravenously 225 mg/kg over 3 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vepoloxamer - High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vepoloxamer injection administered intravenously 450 mg/kg over 3 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5% dextrose in water (D5W)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>D5W administered intravenously over 3 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vepoloxamer</intervention_name>
    <arm_group_label>Vepoloxamer - Low dose</arm_group_label>
    <arm_group_label>Vepoloxamer - High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>5% dextrose in water</intervention_name>
    <arm_group_label>5% dextrose in water (D5W)</arm_group_label>
    <other_name>D5W</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 through 74

          -  Duration of documented heart failure &gt;3 months

          -  On stable concomitant medication regimen ≥4 weeks

          -  Left ventricular ejection fraction ≤35%

          -  Systolic blood pressure ≥90 mmHg

        Exclusion Criteria:

          -  Severe valvular stenosis or primary valvular regurgitation as the cause of heart
             failure

          -  History of myocardial infarction, coronary artery bypass graft surgery, or
             percutaneous intervention within the prior 3 months

          -  Estimated glomerular filtration rate ≤45 mL/min/1.73 m2

          -  Acutely decompensated heart failure within 1 month prior to the screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edwin L. Parsley, D.O.</last_name>
    <role>Study Director</role>
    <affiliation>Mast Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Cardiff</city>
        <state>New South Wales</state>
        <zip>2285</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

